Genzyme ($GENZ) meets FDA consent decree deadline

Genzyme ($GENZ), subject to a hostile bid by Sanofi-Aventis ($SNY), said it has satisfied a key component of a consent decree imposed by U.S. regulators after a crisis at its Boston manufacturing facility led to shortages of two key drugs. Report

Suggested Articles

The eight-year deal will initially cover lupus drug Benlysta and could expand to other GSK specialty-care products in the future.

Amarin had big plans for Vascepa after a big label expansion last year, but it lost a patent fight—and now a generic has won FDA approval.

Intercept Pharmaceuticals, eager to market its potential nonalcoholic steatohepatitis medicine obeticholic acid, will have to keep waiting.